Panion & Bf Biotech (TPE:1760) LT-Debt-to-Total-Asset : 0.04 (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Panion & Bf Biotech LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Panion & Bf Biotech's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.04.

Panion & Bf Biotech's long-term debt to total assets ratio increased from Mar. 2023 (0.02) to Mar. 2024 (0.04). It may suggest that Panion & Bf Biotech is progressively becoming more dependent on debt to grow their business.

Panion & Bf Biotech LT-Debt-to-Total-Asset Historical Data

The historical data trend for Panion & Bf Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panion & Bf Biotech LT-Debt-to-Total-Asset Chart

Panion & Bf Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.24

0.06

0.02

0.05

Panion & Bf Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.02	0.03	0.03	0.05	0.04

Panion & Bf Biotech LT-Debt-to-Total-Asset Calculation

Panion & Bf Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	147.626	/	3235.181
	=	0.05

Panion & Bf Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	136.494	/	3176.439
	=	0.04

Panion & Bf Biotech (TPE:1760) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Panion & Bf Biotech LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Panion & Bf Biotech's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Panion & Bf Biotech (TPE:1760) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panion & Bf Biotech Inc (TPE:1760) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3, Park Street, 16th Floor, F Building, Nangang District, Taipei, TWN, 11503

Website

https://www.pbf.com.tw

Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. It is engaged in research and development of pharmaceuticals and new drugs. It focuses on pharmaceuticals, cosmeceuticals, nutraceuticals, and medical devices sectors. It has four core business groups such as disease treatment, disease prevention, disease diagnosis, and delayed aging. It has two geographic segments Taiwan segment and China, Hong Kong, and Macau segment. It generate majority of the revenue from Taiwan segment.

Panion & Bf Biotech (TPE:1760) Headlines

No Headlines